NIH-funded research R01 grant

Genetic analysis of UBQLN2-related neurodegenerative disease in ALS/FTD

Official title: Genetic analysis of UBQLN2-associated neurodegeneration in frontotemporal dementia

Funded at University of Wisconsin-Madison · NIH-11376726 · Data updated 2026-11-12

Researchers are studying how UBQLN2 gene changes contribute to ALS and frontotemporal dementia to better understand why these diseases develop.

More Dementia research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Wisconsin-Madison
NIH-funded
Lab location1 site (Madison, United States)
Project startSeptember 15, 2020
Project endMarch 31, 2031
Funding year2026
Award (this year)$545,241
NIH project number2R01AG069483-03A1
Project IDNIH-11376726 on NIH RePORTER

Who could benefit from this research

Could help

Patients with UBQLN2-related ALS/FTD or related UBQLN2 mutations, and healthy donors for iPSC controls.

Less likely to help

People without UBQLN2-related neurodegenerative disease are unlikely to directly benefit.

What this research studies

This project looks at how mutations in UBQLN2 cause neurodegeneration by combining fruit-fly genetics with human neuron models derived from patients’ cells. Using a fly-to-human approach, scientists identify pathways that make UBQLN2 toxicity worse and then test these findings in iPSC-derived motor neurons carrying ALS-associated UBQLN2 mutations. A special multi-mutation UBQLN2 variant, 4XALS, helps reveal disease mechanisms without simply overexpressing the protein. The goal is to map disease processes and point toward potential intervention strategies for ALS/FTD.

Why it matters

Potential benefit: If successful, the work could reveal targets to slow or halt UBQLN2-related neurodegeneration and inform future therapies for ALS/FTD patients.

How similar studies have gone: Previous studies using Drosophila models and patient-derived neurons have begun linking UBQLN2 dysfunction to disease pathways, supporting progress but needing validation in human cells.

Where this research is happening

  • University of Wisconsin-Madison
    Madison, United States
    Active

Researchers

  • Principal investigator: Tibbetts, Randal Scot — University of Wisconsin-Madison
  • Study coordinator: Tibbetts, Randal Scot

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.